The Mount Sinai conference on the pharmacotherapy of schizophrenia.
This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.
Marder
Stephen R
SR
VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA. marder@ucla.edu
Essock
Susan M
SM
Miller
Alexander L
AL
Buchanan
Robert W
RW
Davis
John M
JM
Kane
John M
JM
Lieberman
Jeffrey
J
Schooler
Nina R
NR
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D019091:Critical Pathways; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D019317:Evidence-Based Medicine; D006801:Humans; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents